Clinical Trials Logo

CDKL5 clinical trials

View clinical trials related to CDKL5.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06448663 Recruiting - CDKL5 Clinical Trials

Targeting the Gut to Improve Seizure Control in CDKL5 Deficiency Disorder (CDD)

NUTRIENT
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Standard anti-seizure medications have limited efficacy in seizure control in cyclin-dependent kinase-like 5 deficiency disorder (CDD). The study will investigate whether targeting the gut-microbiota-brain axis in CDD patients can alleviate seizures and ameliorate other comorbidities.

NCT ID: NCT05558371 Recruiting - Clinical trials for CDKL5 Deficiency Disorder

International CDKL5 Clinical Research Network

ICCRN
Start date: February 15, 2021
Phase:
Study type: Observational

Pathogenic variants in the Cyclin-dependent kinase like 5 (CDKL5) gene cause CDKL5 deficiency disorder (CDD, MIM 300672, 105830), a severe developmental and epileptic encephalopathy associated with cognitive and motor impairments and cortical visual impairment. While capability for disease modifying therapies is accelerating, there is a critical barrier for clinical trial readiness that may result in failure of these therapies, not due to lack of efficacy but due to lack of validated outcome measures and biomarkers. The measures and biomarkers validated here will be adaptable to other developmental and epileptic encephalopathies.